Citations

Clear

1794 citation(s) found for "Yu, Stephanie".

RADI-04. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933
Bovi, Joseph , Pugh, Stephanie L. , Sabesevitz, David, Paulson, E.S. , Gondi, Vinai , Pinover, Wayne H., Chao, Samuel T. , Machtay, Mitchell , DeNittis, Albert S., Laack, Nadia, Greenspoon, Jeffrey , Mannel, Robert S., Dominello, M.M., Kachnic, Lisa A. , Robinson, Clifford G. , Mehta, Minesh P. , Kundapur, Vijayananda , Huang, Jiayi

Mayo Clinic

Neuro-Oncology Advances | August 12, 2019 | Volume: 1 | Issue: Supplement_1 | Pages: i22-i22

10.1093/noajnl/vdz014.097 Get It

Abstract PURPOSE: RTOG 0933 demonstrated benefits to memory following HA-WBRT, supporting the hypothesis of hippocampal radiosensitivity and associated memory specificity. However, some patients demonstrated cognitive decline, suggesting mechanisms outside hippocampal radiosensitivity playing a role. WMI has been implicated in RT-induced cognitive decline. This secondary analysis explored the relationship between pre-treatment WMI and memory following HA-WBRT. METHODS AND MATERIALS: 113 patients received HA-WBRT. Standardized cognitive assessments were performed at baseline, 2, 4, and 6 months. The primary endpoint was Hopkins Verbal Learning Test Delayed Recall (HVLT-DR) at 4 mos. Secondary endpoints included HVLT Total Recall (HVLT-TR) and Recognition (HVLT-Recog). Of 113 patients, 34 underwent pre-treatment and 4-month post-treatment HVLT testing and pre-treatment post-contrast volumetric T1 and axial T2/FLAIR MRI. Volumetric analysis of metastatic disease burden and disease-unrelated WMI was conducted on the pre-treatment MRI. Correlational analyses were performed examining the relationship between pre-treatment WMI and HVLT outcomes following HA-WBRT. RESULTS: Correlation was found between larger volumes of pre-treatment WMI and decline in HVLT-Recog (r=.54, p< .05) and a correlational trend was observed between larger volume of pre-treatment WMI and decline in HVLT-DR (r=.31, p=.08). Patients with higher pre-treatment disease burden experienced a greater magnitude of stability or positive shift in HVLT-recall and –delayed recall following HA-WBRT. (r=-.36 and r=-.36, p’s < .05), compared to the magnitude of stability/positive shift in those with lesser disease burden. CONCLUSION: In patients receiving HA-WBRT, pre-treatment-WMI predicts memory decline, suggesting white matter integrity pre-treatment contributes to the pathogenesis of post-WBRT cognitive toxicity independent of hippocampal stem cell radiosensitivity. Less decline or improvement in HVLT following HA-WBRT for patients with higher pre-treatment intracranial metastatic burden supports the importance of WBRT-induced intracranial control on cognition. These imaging biomarkers for cognitive toxicity will be further explored on NRG CC001 and CC003, phase III trials of WBRT with or without HA.
Abstract 873: Molecular mechanisms of non-small cell lung cancer growth and drug resistance
Astone, Matteo , Liu, Ping , Coyle, Abbygail M. , Dankert, Erin N. , Hoffman, Dane K. , Hall, Stephanie R., Kuang, Rui , Roden, Anja C. , Alam, Sk. Kayum , Wang, Li , Zhang, Wei , Mansfield, Aaron S. , Hoeppner, Luke H.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 873-873

10.1158/1538-7445.am2019-873 Get It

Abstract Lung cancer is the deadliest and most frequently diagnosed type of tumor worldwide, with 1.6 million deaths reported annually. Non-small cell lung cancer (NSCLC) represents 85% of all lung cancer cases and carries a poor 5-year survival rate below 15%. Prognoses remain dismal due to the large number of patients diagnosed with advanced stage disease and the development of resistance to current therapies. A better understanding of acquired drug resistance will help to circumvent the progression of lung cancer and make significant strides in improving NSCLC patient treatment. Our recent work demonstrates that dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32) and its amino-terminally truncated splice variant (t-DARPP) promote lung tumor growth in orthotopic mouse models. IHC staining of 62 human lung adenocarcinoma tissues showed that t-DARPP expression is elevated with increasing tumor (T) staging score, which represents the size of the primary tumor and whether it has grown into nearby areas, as a metric of tumor progression and growth. Correspondingly, a computational biology analysis of 513 lung adenocarcinoma patients revealed upregulation of t-DARPP isoform expression correlates with advanced T stage and is associated with poor overall survival. We identified a novel physical interaction between DARPP-32 and inhibitory kappa B kinase-α (IKKα) that promotes NSCLC cell migration through activation of non-canonical NF-κB2 signaling. It has been shown that DARPP-32 overexpression inhibits gefitinib-induced apoptosis in gastric cancer and t-DARPP contributes to the trastuzumab resistance phenotype in breast cancer. Our recent findings suggest DARPP-32 and t-DARPP overexpression in NSCLC promotes resistance to specific molecular targeted inhibitors by enabling tumor cells to evade apoptosis via Akt- and Erk-dependent cell survival mechanisms. Current ongoing studies are focused on manipulating expression of DARPP-32 isoforms in lung tumor cells to prevent resistance to targeted therapies in NSCLC patients. Citation Format: SK Kayum Alam, Matteo Astone, Ping Liu, Li Wang, Abbygail M. Coyle, Erin N. Dankert, Dane K. Hoffman, Stephanie R. Hall, Wei Zhang, Rui Kuang, Anja C. Roden, Aaron S. Mansfield, Luke H. Hoeppner. Molecular mechanisms of non-small cell lung cancer growth and drug resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 873.
Correlation Between Kappa Prozone Effect and IgA Kappa M Proteins in Serum Free Light-Chain Assay
Turner, Katherine A., Eckelkamp, Laura L, Kalass, Stephanie, Martinez, Mark, Brewer, Hayley R, Hoyne, Jonathan , Snyder, Melissa R. , Murray, David , Kalass, Stephanie J, Martinez, Mark A, Hoyne, Jonathan B, Murray, David L., Willrich, Maria A V, Martinez, Mark A, Willrich, Maria Alice V.

Mayo Clinic

Clinical Chemistry | August 6, 2019 | Volume: 65 | Issue: 10 | Pages: 1327-1329

10.1373/clinchem.2019.306456 | PMID 31387883 Get It

Magnetic Resonance–guided High-intensity Focused Ultrasound (MRgHIFU) Virtual Treatment Planning for Abdominal Neuroblastoma Utilizing Retrospective Diagnostic 3D CT Images
Tung, Stephanie , Lamberti-Pasculli, Maria, Waspe, Adam C. , Pichardo, Samuel , Gerstle, Justin T. , Fahy, Aodhnait S.

Mayo Clinic

Journal of Pediatric Hematology/Oncology | July 30, 2019 | Volume: 41 | Issue: 7 | Pages: e443-e449

10.1097/mph.0000000000001563 | PMID 31449496 Get It

Magnetic resonance–guided high-intensity focused ultrasound (MRgHIFU) is a novel treatment for neuroblastoma using ultrasound-induced thermal ablation with real-time MR thermometry. It is unclear which patients would be amenable to MRgHIFU given the retroperitoneal location of many neuroblastomas within the smaller pediatric abdomen. In addition, planning relies on MR scans, which are not routine in the standard pediatric neuroblastoma workup. This study sought to demonstrate that neuroblastomas are targetable with MRgHIFU and available computed tomographic imaging could be utilized for MRgHIFU virtual treatment. Cross-sectional images of 88 pediatric abdominal neuroblastoma patients were retrospectively processed with custom software to be made compatible with the Sonalleve MRgHIFU platform. Targetability measured percent treatment to lesion volume, within adequate safety margins from critical structures. All images were successfully converted into treatment planning files. Median lesion size was 191±195 cm3 and depth was 29±17 mm. Up to 78 (85%) patients had targetable lesions with a median targetable volume of 15% and ranging up to 79%. Targetability was highest in superficial, right upper quadrant lesions >200 cm3, but limited by proximity to bowel and ribs. This study demonstrates the capacity for MRgHIFU to potentially treat the majority of abdominal neuroblastomas and the feasibility of using computed tomographic images for MRgHIFU virtual treatment planning.
Genome-wide association study of cerebral small vessel disease reveals established and novel loci
Chung, Jaeyoon , Marini, Sandro , Pera, Joanna, Norrving, Bo, Jiménez-Conde, Jordi , Roquer, Jaume, Tirschwell, David L, Brown, Devin L. , Silliman, Scott, Worrall, Bradford B. , Demel, Stacie L , Greenberg, Steven M. , Słowik, Agnieszka , Lindgren, Arne, Schmidt, Reinhold , Sargurupremraj, Muralidharan , Tiedt, Steffen, Malik, Rainer, Debette, Stéphanie , Dichgans, Martin , Langefeld, Carl D. , Woo, Daniel , Anderson, Christopher D. , Tirschwell, David , Marini, Sandro , Dichgans, Martin , Debette, Stephanie , Fernández‐Cadenas, Israel , Selim, Magdy H. , Meschia, James F. , Lindgren, Arne, Traylor, Matthew , Tiedt, Steffen , Rosand, Jonathan M.

Mayo Clinic

Brain | July 10, 2019 | Volume: 142 | Issue: 10 | Pages: 3176-3189

10.1093/brain/awz233 | PMID 31430377 Get It

Intracerebral haemorrhage (ICH) and small vessel ischaemic stroke (SVS) are the most severe manifestations of cerebral small vessel disease. In a cross-phenotype genome-wide association analysis, Chung et al. identify two novel associations at 2q33 and 13q34 plus a previously identified locus at 1q22 for non-lobar ICH and SVS risk.
A Critical Analysis of Medicare Claims for Otolaryngology Procedures
Youssef, Stephanie J. , Vyas, Krishna S.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 25, 2019 | Volume: 161 | Issue: 6 | Pages: 929-938

10.1177/0194599819858584 | PMID 31237824 Get It

ObjectiveThis study was performed to outline and analyze the overall Medicare landscape with respect to otolaryngologists and beneficiaries, services, and reimbursements.MethodsThis is a retrospective analysis of publicly available Medicare utilization and payment data for all otolaryngologists in facility and nonfacility practice settings who provided services to Medicare beneficiaries between January 1, 2012, and December 31, 2016.ResultsIn 2016, a total of $701,195,375 was distributed to 8572 otolaryngology physician providers for 815 unique Healthcare Common Procedure Coding System codes for 13,942,536 procedure claims. Of specialty care, otolaryngology ranks 20th among 54 subspecialties for total Medicare payments. The average number of services coded per provider was 1627. The average otolaryngologist was paid $81,800.67. Thirty‐two percent of otolaryngologists did not receive reimbursement for services from Medicare in 2016.DiscussionIn 2016, the most significant contributors to Medicare payments to otolaryngologists were large‐scale, low‐cost events that are relatively short procedures done in clinic. Utilization of nasal endoscopy was up trending from 2012 to 2016. Some of the Current Procedural Terminology codes with the greatest discrepancies between submitted charge and Medicare payment among nonfacility otolaryngology providers are more involved than simple office procedures.Implications for PracticeIt is increasingly valuable for physicians to know factors that affect reimbursement for procedures and operations in different settings and to be aware of the trends in variation in their specialty. Otolaryngologists should communicate with policy makers in efforts toward sustainable reimbursement models.
SMART goals setting and biometric changes in obese adults with multimorbidity: Secondary analysis of a randomized controlled trial
Takahashi, Paul Y. , Quigg, Stephanie, Croghan, Ivana T. , Schroeder, Darrell R. , Ebbert, Jon O. , Quigg, Stephanie M, Takahashi, Paul , Schroeder, Darrell

Mayo Clinic

SAGE Open Medicine | June 24, 2019 | Volume: 7 | Issue: No issue available | Pages: No page available

10.1177/2050312119858042 | PMID 31258905 Get It

Objectives: Clinicians recommend diet and exercise for overweight/obese patients. We conducted a secondary analysis of a randomized controlled clinical trial evaluating goal setting and pedometer use versus usual care on weight, waist circumference, and blood pressure of patients with multiple chronic conditions. Methods: In this trial, we recruited and randomized patients over 18 years with multiple chronic conditions. There were two groups with an immediate intervention group who received behavioral coaching and a pedometer versus a delayed control who received the intervention after 2 months. We evaluated body weight, waist circumference, and blood pressure as outcomes. We used analysis of covariance to evaluate differences between the intervention and the control groups. Results: Of 130 patients, mean age was 63.4 years (SD, 17.3). At 2 months, intervention participants lost 0.2 kg versus a 0.1-kg gain in the control participants ( P = .44). The immediate intervention group had significantly smaller waist circumference change at 2-month follow-up compared to control at −1.6 cm (95% confidence interval = −3.1 to −0.1), which was driven by an increase in waist circumference in the delayed control group. No difference in systolic blood pressure was observed. Discussion: We observed no difference in weight or blood pressure between the groups with obesity and multiple chronic conditions.
Health Misinformation and the Power of Narrative Messaging in the Public Sphere
Murdoch, Blake , Brown, Jasmine M., Perrault, Sarah Tinker, Jarry, Jonathan, Anthony, Samantha J. , Ogbogu, Ubaka , Greenberg, Joshua , Zarzeczny, Amy , Hyde-Lay, Robyn, Caulfield, Timothy , Marcon, Alessandro R , Snyder, Jeremy , Brooks, Stephanie P. , Master, Zubin , Rachul, Christen M.

Mayo Clinic

Canadian Journal of Bioethics | June 18, 2019 | Volume: 2 | Issue: 2 | Pages: 52-60

10.7202/1060911ar Get It

Numerous social, economic and academic pressures can have a negative impact on representations of biomedical research. We review several of the forces playing an increasingly pernicious role in how health and science information is interpreted, shared and used, drawing discussions towards the role of narrative. In turn, we explore how aspects of narrative are used in different social contexts and communication environments, and present creative responses that may help counter the negative trends. As traditional methods of communication have in many ways failed the public, changes in approach are required, including the creative use of narratives.
DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility
Pardini, Barbara , Corrado, Alda, Berndt, Sonja I. , Brenner, Hermann , Caan, Bette J. , Casey, Graham , Chang‐Claude, Jenny , Gala, Manish , Gallinger, Steven , Haile, Robert W. , Harrison, Tabitha A. , Hayes, Richard B. , Hoffmeister, Michael , Huyghe, Jeroen R. , Jenkins, Mark A. , Lindor, Noralane M. , Nan, Hongmei , Slattery, Martha L. , Vodičková, Ludmila, Vodička, Pavel , Gemignani, Federica , Peters, Ulrike , Naccarati, Alessio , Hoffmeister, Michael , Slattery, Martha L , Jenkins, Mark A , Haile, Robert W , Harrison, Tabitha A , Brenner, Hermann , Hayes, Richard B , Nan, Hongmei , Vodicka, Pavel , Caan, Bette J , Paolicchi, Elisa , Cugliari, Giovanni , Bezieau, Stéphane , Bien, Stephanie A. , Campbell, Peter T. , Chan, Andrew T. , Cotterchio, Michelle , Hopper, John L. , Marchand, Loı̈c Le , Lin, Yi , Newcomb, Polly A. , Ogino, Shuji , Potter, John D. , Schoen, Robert E. , White, Emily E. , Vymetalkova, Veronika Polakova , Landi, Stefano

Mayo Clinic

International Journal of Cancer | June 18, 2019 | Volume: 146 | Issue: 2 | Pages: 363-372

10.1002/ijc.32516 | PMID 31209889 Get It

Interindividual differences in DNA repair systems may play a role in modulating the individual risk of developing colorectal cancer. To better ascertain the role of DNA repair gene polymorphisms on colon and rectal cancer risk individually, we evaluated 15,419 single nucleotide polymorphisms (SNPs) within 185 DNA repair genes using GWAS data from the Colon Cancer Family Registry (CCFR) and the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), which included 8,178 colon cancer, 2,936 rectum cancer cases and 14,659 controls. Rs1800734 (in MLH1 gene) was associated with colon cancer risk (p‐value = 3.5 × 10−6) and rs2189517 (in RAD51B) with rectal cancer risk (p‐value = 5.7 × 10−6). The results had statistical significance close to the Bonferroni corrected p‐value of 5.8 × 10−6. Ninety‐four SNPs were significantly associated with colorectal cancer risk after Binomial Sequential Goodness of Fit (BSGoF) procedure and confirmed the relevance of DNA mismatch repair (MMR) and homologous recombination pathways for colon and rectum cancer, respectively. Defects in MMR genes are known to be crucial for familial form of colorectal cancer but our findings suggest that specific genetic variations in MLH1 are important also in the individual predisposition to sporadic colon cancer. Other SNPs associated with the risk of colon cancer (e.g., rs16906252 in MGMT) were found to affect mRNA expression levels in colon transverse and therefore working as possible cis‐eQTL suggesting possible mechanisms of carcinogenesis.
PS1337 IVOSIDENIB (AG‐120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1‐MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY
Foran, James M. , Watts, Justin M. , Stein, E.M., Fathi, Amir T. , Prince, Gabrielle T., Stein, A.S., Stone, Richard M. , Patel, Pankaj , Tallman, Martin S. , Wang, Heng-Xiang, Zhang, V., Dai, D. , Fan, Bin , Yen, K.E., Kapsalis, Stephanie M., Hickman, D. , Agresta, Sam, Liu, H., Wu, Bor-Wen, Attar, Eyal C. , Kantarjian, H., DiNardo, Courtney D. , Botton, Stéphane de , Patel, P.A., Choe, Sung

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 610-611

10.1097/01.hs9.0000563628.38037.c3 Get It

Background:Mutations in isocitrate dehydrogenase 1 (IDH1) occur in ∼4% of patients with myelodysplastic syndrome (MDS) and have been linked with increased transformation to acute myeloid leukemia (AML). Ivosidenib (IVO; AG‐120) is an oral, potent, targeted inhibitor of the mutant IDH1 protein (mIDH1) that is approved for the treatment of adults with mIDH1 relapsed or refractory (R/R) AML. Through inhibition of mIDH1, IVO suppresses production of the oncometabolite 2‐hydroxyglutarate, leading to clinical responses via differentiation of malignant cells.Aims:To report safety and efficacy data from patients with R/R MDS enrolled in the first‐in‐human, phase 1, dose escalation and expansion study of IVO in patients with mIDH1 advanced hematologic malignancies (NCT02074839).Methods:This ongoing study is evaluating the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and clinical activity of IVO. Enrollment was completed on May 8, 2017. In dose escalation, patients received single‐agent IVO orally (dose range, 200–1200 mg daily) in 28‐day cycles. The MTD was not reached and 500 mg QD was selected as the dose for expansion. The overall response rate (ORR) for MDS was defined as complete remission (CR) + partial remission + marrow CR (mCR) according to International Working Group 2006 criteria for MDS. Exploratory biomarker assessments included baseline co‐occurring mutations (next‐generation sequencing panel for hematologic malignancies) and mIDH1 variant allele frequency (VAF) in bone marrow mononuclear cells (BEAMing Digital PCR; lower limit of detection for mIDH1, 0.02–0.04%).Results:Baseline characteristics of the 12 patients with R/R MDS who received 500 mg IVO once daily were: 9 men/3 women; median age 72.5 years (range 52–78), and 42% were ≥75 years of age; median number of prior therapies 1 (range 1–3). As of Nov 2, 2018, 3 of 12 (25.0%) patients remained on treatment; 9 (75.0%) had discontinued (one for allogeneic stem cell transplantation). Median duration of exposure to IVO was 11.4 months (range 3.3–42.5). Adverse events (AEs) of any grade, irrespective of causality, occurring in ≥20% of the 12 patients were diarrhea, fatigue, back pain, rash (n = 4 each, 33.3%), anemia, urinary tract infection, decreased appetite, hypokalemia, arthralgia, dyspnea, pruritus, and hypotension (n = 3 each, 25.0%). No AEs led to permanent discontinuation of treatment. IDH differentiation syndrome was observed in 1 of 12 (8.3%) patients (grade 2). Electrocardiogram QT prolonged was reported in 2 of 12 patients (17%; grade 1 in 1 patient and grade 2 in 1 patient). Five of 12 patients achieved CR (41.7%; 95% CI 15.2%, 72.3%), 1 achieved PR (8.3%), and 5 achieved mCR (41.7%), resulting in an ORR of 91.7% (95% CI 61.5%, 99.8%). The median duration of CR was not estimable (NE) at the time of datacutoff and the median duration of response was 21.4 months (95% CI 2.3, NE). At 12 months, 60.0% of patients remained in CR. Among 5 patients who were transfusion dependent at baseline, 4 became transfusion independent for ≥56 consecutive days on treatment. Baseline co‐occurring mutations and changes in mIDH1 VAF levels will be presented.Summary/Conclusion:In patients with mIDH1 R/R MDS, IVO monotherapy was well tolerated and induced durable remissions and transfusion independence. These findings support the role of IVO as an effective, oral, targeted treatment for patients with mIDH1 R/R MDS.